Overview

Pericapsular Nerve Group Block (PENG) for Hip Surgery

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
0
Participant gender:
All
Summary
This will be a randomized comparison of pericapsular nerve group (PENG) blocks with bupivacaine and a placebo control (PENG blocks with normal saline). The overall objective of the proposed research is to determine the relative risks and benefits of a single-injection PENG block to provide postoperative analgesia following hip arthroscopy. Hypothesis 1: Following hip arthroscopy, participants with a PENG block will experience less pain in the recovery room compared with current standard-of-care as measured with the Numeric Rating Scale (NRS). Hypothesis 2: Following hip arthroscopy, participants with a PENG block will consume less opioid in the operating and recovery rooms compared with current standard-of-care as measured in oral morphine milligram equivalents. Primary end point: In order to claim that PENG blocks are superior to placebo overall, at least one of these two hypotheses must demonstrate PENG superiority while the other cannot demonstrate inferiority.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Bupivacaine
Criteria
Inclusion Criteria:

- undergoing unilateral primary hip arthroscopy with at least moderate postoperative
pain anticipated

- analgesic plan includes a general anesthetic

- age 18 years or older

Exclusion Criteria:

- morbid obesity as defined by a body mass index > 40 (BMI=weight in kg / [height in
meters]2)

- any planned regional analgesic or anesthetic

- chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use
> 4 weeks)

- history of opioid abuse

- any comorbidity which results in moderate or severe functional limitation

- inability to communicate with the investigators or hospital staff

- pregnancy

- incarceration

- any reason for increased risk of a peripheral nerve block (e.g. anticoagulation)